An in vivo platform for tumor biomarker assessment.
Tumor biomarkers provide a quantitative tool for following tumor progression and response to therapy. However, investigations of clinically useful tumor biomarkers are time-consuming, costly, and limited by patient and tumor heterogeneity. In addition, assessment of biomarkers as indicators of thera...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3202552?pdf=render |
id |
doaj-d8cb9ce1093f4d6eaba681074c48e6cd |
---|---|
record_format |
Article |
spelling |
doaj-d8cb9ce1093f4d6eaba681074c48e6cd2020-11-25T02:55:56ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-01610e2672210.1371/journal.pone.0026722An in vivo platform for tumor biomarker assessment.Elliot L ServaisKei SuzukiChristos ColovosLuis RodriguezCamelia SimaMartin FleisherValerie W RuschMichel SadelainPrasad S AdusumilliTumor biomarkers provide a quantitative tool for following tumor progression and response to therapy. However, investigations of clinically useful tumor biomarkers are time-consuming, costly, and limited by patient and tumor heterogeneity. In addition, assessment of biomarkers as indicators of therapy response is confounded by the concomitant use of multiple therapeutic interventions. Herein we report our use of a clinically relevant orthotopic animal model of malignant pleural mesothelioma for investigating tumor biomarkers. Utilizing multi-modality imaging with correlative histopathology, we demonstrate the utility and accuracy of the mouse model in investigating tumor biomarkers--serum soluble mesothelin-related peptide (SMRP) and osteopontin (OPN). This model revealed percentage change in SMRP level to be an accurate biomarker of tumor progression and therapeutic response--a finding consistent with recent clinical studies. This in vivo platform demonstrates the advantages of a validated mouse model for the timely and cost-effective acceleration of human biomarker translational research.http://europepmc.org/articles/PMC3202552?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Elliot L Servais Kei Suzuki Christos Colovos Luis Rodriguez Camelia Sima Martin Fleisher Valerie W Rusch Michel Sadelain Prasad S Adusumilli |
spellingShingle |
Elliot L Servais Kei Suzuki Christos Colovos Luis Rodriguez Camelia Sima Martin Fleisher Valerie W Rusch Michel Sadelain Prasad S Adusumilli An in vivo platform for tumor biomarker assessment. PLoS ONE |
author_facet |
Elliot L Servais Kei Suzuki Christos Colovos Luis Rodriguez Camelia Sima Martin Fleisher Valerie W Rusch Michel Sadelain Prasad S Adusumilli |
author_sort |
Elliot L Servais |
title |
An in vivo platform for tumor biomarker assessment. |
title_short |
An in vivo platform for tumor biomarker assessment. |
title_full |
An in vivo platform for tumor biomarker assessment. |
title_fullStr |
An in vivo platform for tumor biomarker assessment. |
title_full_unstemmed |
An in vivo platform for tumor biomarker assessment. |
title_sort |
in vivo platform for tumor biomarker assessment. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2011-01-01 |
description |
Tumor biomarkers provide a quantitative tool for following tumor progression and response to therapy. However, investigations of clinically useful tumor biomarkers are time-consuming, costly, and limited by patient and tumor heterogeneity. In addition, assessment of biomarkers as indicators of therapy response is confounded by the concomitant use of multiple therapeutic interventions. Herein we report our use of a clinically relevant orthotopic animal model of malignant pleural mesothelioma for investigating tumor biomarkers. Utilizing multi-modality imaging with correlative histopathology, we demonstrate the utility and accuracy of the mouse model in investigating tumor biomarkers--serum soluble mesothelin-related peptide (SMRP) and osteopontin (OPN). This model revealed percentage change in SMRP level to be an accurate biomarker of tumor progression and therapeutic response--a finding consistent with recent clinical studies. This in vivo platform demonstrates the advantages of a validated mouse model for the timely and cost-effective acceleration of human biomarker translational research. |
url |
http://europepmc.org/articles/PMC3202552?pdf=render |
work_keys_str_mv |
AT elliotlservais aninvivoplatformfortumorbiomarkerassessment AT keisuzuki aninvivoplatformfortumorbiomarkerassessment AT christoscolovos aninvivoplatformfortumorbiomarkerassessment AT luisrodriguez aninvivoplatformfortumorbiomarkerassessment AT cameliasima aninvivoplatformfortumorbiomarkerassessment AT martinfleisher aninvivoplatformfortumorbiomarkerassessment AT valeriewrusch aninvivoplatformfortumorbiomarkerassessment AT michelsadelain aninvivoplatformfortumorbiomarkerassessment AT prasadsadusumilli aninvivoplatformfortumorbiomarkerassessment AT elliotlservais invivoplatformfortumorbiomarkerassessment AT keisuzuki invivoplatformfortumorbiomarkerassessment AT christoscolovos invivoplatformfortumorbiomarkerassessment AT luisrodriguez invivoplatformfortumorbiomarkerassessment AT cameliasima invivoplatformfortumorbiomarkerassessment AT martinfleisher invivoplatformfortumorbiomarkerassessment AT valeriewrusch invivoplatformfortumorbiomarkerassessment AT michelsadelain invivoplatformfortumorbiomarkerassessment AT prasadsadusumilli invivoplatformfortumorbiomarkerassessment |
_version_ |
1724715304303460352 |